VAUGHAN, ON — Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...
Affinia Therapeutics Inc. has nominated AFTX-201 as a development candidate for the treatment of BAG3 dilated cardiomyopathy. The gene therapy, using Affinia’s cardiotropic capsid, is given as a ...
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events ...
More than 4.2 million Americans live with glaucoma, a leading cause of vision loss in the nation. Although there is no cure for glaucoma, early detection and treatment can stop this condition in its ...